ArticleChemistry & biodiversity2026
Antibacterial Activity of α-Sulfamidophosphonate Derivatives and Their In Silico Assessment as Dihydropteroate Synthase Binders.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we report the first antibacterial evaluation of a focused library of 12 previously synthesized α-sulfamidophosphonate derivatives (4a-4l) against a panel of nine Gram-positive and Gram-negative strains, including ESBL- and carbapenemase-producing Enterobacterales. The overall hit rate was modest, as most compounds were inactive at the highest tested concentration (MIC ≥ 256 µg/mL), indicating a narrow and strain-selective profile. Nevertheless, selected derivatives showed noteworthy activity against individual isolates: 4 g inhibited Staphylococcus aureus ATCC29213 at 4 µg/mL, 4c inhibited KPC-3-producing Klebsiella pneumoniae at 2 µg/mL, and 4e and 4l inhibited VIM-producing Escherichia coli at 4 µg/mL. Density functional theory (DFT) calculations were used to examine substituent-dependent electronic features, whereas docking and 100 ns molecular dynamics (MD) simulations were employed to test whether the scaffold can adopt plausible binding modes in a dihydropteroate synthase (DHPS) model. Because no biochemical DHPS assay was performed, the computational results should be regarded as hypothesis-generating rather than mechanistic proof. In silico ADMET predictions were used as an exploratory triage step and similarly await experimental validation. Overall, the present work identifies α-sulfamidophosphonates as preliminary antibacterial hits for further optimization, while emphasizing the need for broader microbiology, cytotoxicity, bactericidal, and target-validation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.